Genenta Science (GNTA) Competitors $3.57 +0.07 (+2.11%) Closing price 03:05 PM EasternExtended Trading$3.54 -0.04 (-1.09%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. MREO, SCPH, IMMP, DMAC, TKNO, ZYBT, ALMS, NMRA, PBYI, and GALTShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Mereo BioPharma Group (MREO), scPharmaceuticals (SCPH), Prima BioMed (IMMP), DiaMedica Therapeutics (DMAC), Alpha Teknova (TKNO), Zhengye Biotechnology (ZYBT), Alumis (ALMS), Neumora Therapeutics (NMRA), Puma Biotechnology (PBYI), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Its Competitors Mereo BioPharma Group scPharmaceuticals Prima BioMed DiaMedica Therapeutics Alpha Teknova Zhengye Biotechnology Alumis Neumora Therapeutics Puma Biotechnology Galectin Therapeutics Mereo BioPharma Group (NASDAQ:MREO) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has more risk and volatility, MREO or GNTA? Mereo BioPharma Group has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Do institutionals & insiders hold more shares of MREO or GNTA? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 5.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend MREO or GNTA? Mereo BioPharma Group currently has a consensus price target of $7.20, suggesting a potential upside of 328.57%. Genenta Science has a consensus price target of $25.00, suggesting a potential upside of 599.50%. Given Genenta Science's higher possible upside, analysts clearly believe Genenta Science is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MREO or GNTA more profitable? Genenta Science's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A -80.00% -66.94% Genenta Science N/A N/A N/A Which has preferable valuation and earnings, MREO or GNTA? Genenta Science has lower revenue, but higher earnings than Mereo BioPharma Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$10M26.71-$43.25M-$0.07-24.00Genenta ScienceN/AN/A-$9.64MN/AN/A Does the media favor MREO or GNTA? In the previous week, Mereo BioPharma Group had 29 more articles in the media than Genenta Science. MarketBeat recorded 30 mentions for Mereo BioPharma Group and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.88 beat Mereo BioPharma Group's score of 0.48 indicating that Genenta Science is being referred to more favorably in the news media. Company Overall Sentiment Mereo BioPharma Group Neutral Genenta Science Very Positive SummaryGenenta Science beats Mereo BioPharma Group on 7 of the 13 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.37M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E RatioN/A20.7930.8625.27Price / SalesN/A232.09403.8888.61Price / CashN/A41.5625.2228.45Price / Book4.839.749.516.00Net Income-$9.64M-$54.74M$3.26B$265.34M7 Day Performance1.10%8.13%4.50%2.79%1 Month Performance-5.20%7.74%5.22%1.51%1 Year Performance-15.81%18.08%31.92%25.40% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.7865 of 5 stars$3.57+2.1%$25.00+599.5%-17.0%$65.37MN/A0.007Positive NewsGap UpMREOMereo BioPharma Group2.0677 of 5 stars$1.62+6.3%$7.20+345.8%-59.8%$256.79M$10M-23.0740News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionSCPHscPharmaceuticals4.5021 of 5 stars$4.83+3.6%$14.00+189.9%-11.4%$255.31M$36.33M-2.6530Short Interest ↓IMMPPrima BioMed1.7397 of 5 stars$1.74+2.1%$7.00+303.5%-23.5%$254.68M$5.14M0.002,021Positive NewsGap UpDMACDiaMedica Therapeutics1.7479 of 5 stars$4.91+7.1%$10.75+119.1%+67.5%$254.57MN/A-7.7020Earnings ReportAnalyst ForecastShort Interest ↑TKNOAlpha Teknova2.2221 of 5 stars$4.63+5.0%$10.00+116.0%-5.3%$247.69M$37.74M-11.04240ZYBTZhengye BiotechnologyN/A$5.21-3.2%N/AN/A$245.76M$25.53M0.00278Positive NewsGap UpALMSAlumis2.8211 of 5 stars$4.49+3.3%$19.80+341.5%-62.9%$244.03MN/A0.00N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionNMRANeumora Therapeutics3.1183 of 5 stars$1.51+4.5%$7.14+374.6%-85.5%$243.74MN/A-0.96108Positive NewsPBYIPuma Biotechnology4.2568 of 5 stars$4.84-0.3%$7.00+44.8%+112.6%$243.54M$230.50M4.93200Positive NewsAnalyst UpgradeGALTGalectin Therapeutics2.3901 of 5 stars$3.79-2.3%$6.00+58.2%+53.9%$242.40MN/A-5.329News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies Mereo BioPharma Group Competitors scPharmaceuticals Competitors Prima BioMed Competitors DiaMedica Therapeutics Competitors Alpha Teknova Competitors Zhengye Biotechnology Competitors Alumis Competitors Neumora Therapeutics Competitors Puma Biotechnology Competitors Galectin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access